1-乙基-5-甲基-1H-苯并咪唑 | 17582-97-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-乙基-5-甲基-1H-苯并咪唑
• 英文名称: 1-ethyl-5-methyl-1H-benzo[d]imidazol
• 英文别名: 1-Ethyl-5-methylindazol；1-ethyl-5-methyl-1H-benzoimidazole；1-Ethyl-5-methyl-1H-benzo[d]imidazole；1-ethyl-5-methylbenzimidazole
• CAS: 17582-97-7
• 化学式: C₁₀H₁₂N₂
• 分子量: 160.219
• InChiKey: BPHPQBJNVMVWQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N1-乙基-4-甲基-1,2-苯二胺 、 甲酸 以37%的产率得到
  参考文献：
  名称：

  SAZONOV, S. K.;LYUBICH, M. S., XIMIYA I TEXNOL. GALOGENSEREBRYAN. SVETOCHUVSTVIT. MATER., M.,(1988) S. 6+

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1<br/>[FR] INHIBITEURS DE LA DÉMÉTHYLASE 1 SPÉCIFIQUE DE LA LYSINE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2016037005A1

  公开（公告）日：2016-03-10

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了替代杂环衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物对于抑制赖氨酸特异性去甲基化酶-1是有用的。此外，所述化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等是有用的。
• [EN] ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME<br/>[FR] INHIBITEURS DE L'ACÉTYL-COA SYNTHÉTASE 2 (ACSS2) ET LEURS PROCÉDÉS D'UTILISATION
  申请人：THE WISTAR INST

  公开号：WO2020252407A1

  公开（公告）日：2020-12-17

  The present disclosure provides compounds that are ACSS2 inhibitors. In certain embodiments, the compounds of the disclosure are useful for treating and/or preventing certain types of cancer.

  本公开提供了一些ACSS2抑制剂化合物。在某些实施例中，本公开的化合物可用于治疗和/或预防某些类型的癌症。
• [EN] HER2 MUTATION INHIBITORS<br/>[FR] INHIBITEURS DE MUTATION HER2
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2022003575A1

  公开（公告）日：2022-01-06

  This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用可接受盐，其中L1、L2、R1、R2、R3和n如本文所定义。本发明还涉及包括这些化合物和盐的药物组合物，以及利用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。
• N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
  申请人：ARRAY BIOPHARMA, INC.

  公开号：US20140023643A1

  公开（公告）日：2014-01-23

  This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 2 , R 3 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

  本发明提供了I式化合物，其中B、G、A、E、R1、R2、R3、m和n如本文所定义，它们可用作I型受体酪氨酸激酶抑制剂，并且在哺乳动物的增殖过度疾病治疗中使用的方法。
• BENZIMIDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF
  申请人：INNOV17 LLC

  公开号：US20160024052A1

  公开（公告）日：2016-01-28

  Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

  本文提供了式(I)和式(II)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物，可用于治疗维甲酸受体相关孤儿受体调节的疾病和障碍。